Phase III GRID study of BAY 73-4506 (Bayer HealthCare) for GIST meets primary endpoint - 04-Jun-2012

The Phase III GRID trial evaluating BAY 73-4506 (regorafenib), from Bayer HealthCare, in patients with metastatic and/or unresectable Gastrointestinal Stromal Tumors (GIST) met its primary endpoint. The median PFS was 4.8 months in the BAY 73-4506 arm versus 0.9 months in the placebo arm. The most common adverse events included hand-foot skin reaction (56.1% vs.15.2%), hypertension (48.5% vs. 16.7%) and diarrhea (40.9% vs.7.6%). The data was presented at the Annual Meeting of the American Society of Clinical Oncology. Bayer plans to submit a New Drug Application for regorafenib in GIST in the second half of 2012.

Related News

FDA approves Stivarga (Bayer HealthCare) in patients with GIST

Phase III trial of Stivarga (Bayer HealthCare) finds positive effect in patients with GIST

Bayer HealthCare submit NDA for BAY 73-4506 as treatment for GIST

Phase III GRID study of BAY 73-4506 (Bayer HealthCare) for GIST meets primary endpoint

Regorafenib (Onyx/Bayer) in Phase GRID study for GIST

JAMA publishes Glivec (Novartis) follow up data in GIST

Phase III study of Sufentanil NanoTab PCA System (AcelRx Pharmaceuticals) meets primary endpoint for Pain relief

FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

Phase III study of Sufentanil NanoTab PCA System (AcelRx Pharmaceuticals) meets primary endpoint for...

23 May 2013

Top-line data from a Phase III study of Sufentanil NanoTab PCA System, from AcelRx Pharmaceuticals, shows that the primary efficacy endpoint...

Read full article

FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA

22 May 2013

The Freestyle Insulinx Blood Glucose Monitoring System has been recalled by Abbott Diabetes Care in the United States. The FDA has assigned...

Read full article